Citeline's latest Scrip Asia 100 e-book is live! Visit the microsite to download the report.
While quieter than some recent years, 2024 did produce several clinical trial readouts destined to have an impact on their respective markets. Here, in roughly chronological order, Scrip takes a look at the 10 clinical stories that got readers clicking the most over the past 12 months.
Scrip picks five key themes that dominated biopharma developments in 2024 and look set to continue to influence the industry throughout this year.
Taiwan-based PharmaEssentia hopes to add essential thrombocytopenia to the label for its pegylated interferon product, already approved to treat polycythemia vera.
The Swiss-headquartered, NASDAQ-listed group has posted a Phase II win for OCS-05 in acute optic neuritis, which opens up its potential in additional, and much larger, neuro-ophthalmic indications, CEO Riad Sherif tells Scrip.
While quieter than some recent years, 2024 did produce several clinical trial readouts destined to have an impact on their respective markets. Here, in roughly chronological order, Scrip takes a look at the 10 clinical stories that got readers clicking the most over the past 12 months.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The Swiss-headquartered, NASDAQ-listed group has posted a Phase II win for OCS-05 in acute optic neuritis, which opens up its potential in additional, and much larger, neuro-ophthalmic indications, CEO Riad Sherif tells Scrip.
Plus deals involving Pfizer/Atavistik, Immedica/Marinus, J&J/Kaken, Ikena/Inmagene, Corxel/Vincentage, Rapt/Jemincare, Sanofi/Corxel, Bristol Myers Squibb/BioArctic, NGM/kdT Ventures and more.
The year’s new drugs included the first drug approved for non-alcoholic steatohepatitis (NASH) and two drugs for primary biliary cholangitis (PBC).
Following promising Phase II data presented at ASH on the company's allogenic leukemia-derived dendritic cell vaccine, Mendus has secured support from the FDA and the EMA for pivotal studies starting later this year.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Plus deals involving Pfizer/Atavistik, Immedica/Marinus, J&J/Kaken, Ikena/Inmagene, Corxel/Vincentage, Rapt/Jemincare, Sanofi/Corxel, Bristol Myers Squibb/BioArctic, NGM/kdT Ventures and more.
Restructuring Edition: Vincerx strategic review ends with a merger, Viracta halts last clinical trial and assesses options, and Achilles completed a strategic review by selling assets to AstraZeneca. Also, Synaptogenix explores opportunities, while GenSight warns its cash is running out.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
